<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953159</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-0775</org_study_id>
    <nct_id>NCT01953159</nct_id>
  </id_info>
  <brief_title>Assessment of Paclitaxel-Induced Neuropathy</brief_title>
  <official_title>Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect clinical data, blood samples, and self reported
      symptoms from patients that experience unusually severe neuropathy after treatment with
      paclitaxel. This data will be used to develop predictive markers for neuropathy. Blood
      samples will be used to create induced pluripotent stem (iPS) cells and eventually artificial
      nerve cells to be used to study neuropathy in the lab.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of polygenic risk score</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients will be assessed for neuropathy symptoms and predictive markers at the time of enrollment.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <description>Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without neuropathy</arm_group_label>
    <description>Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Questionnaires</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with paclitaxel
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Severe Toxicity Group):

          -  Diagnosis of cancer (including, but not limited to, breast and ovarian cancer)

          -  Females aged 18 and older

          -  History of grade 3 or higher peripheral neurotoxicity, any neuromotor, neurocortical,
             or neurocerebellar toxicity, myalgias or arthralgias refractory to non-steroidal
             anti-inflammatory drugs and steroids, ong-term persistence (&gt; 6 months) of grade 2 or
             higher peripheral neuropathy, or other unusually severe neurotoxicity approved for
             inclusion in study by Principal Investigator after completion of paclitaxel
             chemotherapy regimen or history of peripheral neuropathy that required treatment with
             narcotics or grade 2 or higher peripheral neuropathy after only 1 to 2 doses of
             paclitaxel.

        Inclusion Criteria (Control Group):

          -  History of no neurotoxicity (grade 0) after completion of a standard
             paclitaxel-containing chemotherapy regimen

          -  Females age 18 and older

          -  Matched to a specified subject with neurotoxicity based on age (within 10 years),
             tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity

        Exclusion Criteria :

          -  Treatment with other severely neurotoxic chemotherapy (i.e. cisplatin) prior to or
             concomitantly with paclitaxel. Carboplatin therapy is allowed.

          -  Presence of peripheral neuropathy prior to paclitaxel therapy

          -  Poorly controlled or insulin-dependent diabetes or other condition likely to
             predispose to neurotoxicity (alcoholism, Charcot-Marie-Tooth disease)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

